Table 1 Participant characteristics
n = 50 | |
|---|---|
Age | 67.2 ± 7.3 |
Male | 46% (23) |
BMI | 25.4 ± 3.5 |
Education | 16.7 ± 2.1 |
CDR | 0 |
MMSE | 29.1 ± 1.1 |
Hypertension | 30% (15) |
Cardiovascular disease | 6% (3) |
Diabetes | 2% (1) |
Thyroid disorders | 18% (9) |
ApoE4+ | 34% (17) |
Ethnicity | |
Caucasian | 84% (42) |
African American | 14% (7) |
Asian | 2% (1) |
CSF (pg/mL)1 | |
Aβ42 median (IQR) | 626.0 (339) |
P-tau181 median (IQR) | 40.1 (21) |
T-tau, median (IQR) | 241.7 (192) |
Preclinical AD groups | |
Amyloid−/Tau− | 24 (48%), 3 (12.5%) ApoE4 carriers |
Amyloid−/Tau+ | 14 (28%), 6 (42.9%) ApoE4 carriers |
Amyloid+/Tau− | 8 (16%), 4 (50%) ApoE4 carriers |
Amyloid+/Tau+ | 4 (8%), 4 (100%) ApoE4 carriers |
Sleep | |
ESS | 5.9 ± 3.7 |
AHI4% (IQR) | 1.2 (2.9) |
AHI-all (IQR) | 8.5 (7.8) |
Arousal Index | 19.7 ± 7.6 |
O2 Saturation | 94.4 ± 1.7 |
In-lab TST (hrs.) | 6.0 ± 1.0 |
Latency to sleep (min.) | 11.7 ± 12.7 |
Latency to REM (min.) | 99.2 ± 61.9 |
WASO (min.) | 91.5 ± 58.3 |
SE (%) | 78.3 ± 11.9 |
N1 (% of TST) | 20.4 ± 8.3 |
N2 (% of TST) | 43.6 ± 10.8 |
N3 (% of TST) | 17.6 ± 10.8 |
REM (% of TST) | 18.4 ± 4.9 |
Habitual TST (hrs.) | 7.2 ± 1.0 |